NCT05722717|Unknown
Genetic Risk Factors for Multi-system Inflammatory Syndrome in Children and Pediatric Post COVID Condition
GRIP
Loading search results
GRIP
Sponsor study identifier
observational
400
1 country
1
Study Start
June 28, 2022
Actual (reported)Primary Completion
January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
We will perform Whole Exome Sequencing on DNA from saliva. We will include: Children with a history of MIS-C; children with post-COVID condition; and controls in order to identify rare, high impact genetic variants in immunological genes and pathways in children with a history of MIS-C or pediatric post-COVID condition.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 28, 2022
Actual (reported)February 9, 2023
Actual (reported)February 10, 2023
Actual (reported)January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Quantity and quality of genetic variants in immunological genes between study groups.
We want to quantify how many immunogenic variants are found between the groups and identify which variants/genes these are.
2 year
Correlate genetic findings with clinical characteristics
2 year
Children with a history of MIS-C: as defined according to WHO criteria, who were 0-18 at the time of MIS-C.
Children with post-COVID condition who were 0-18 at the time of SARS-CoV-2 infection: as defined according to the WHO case definition.
'Exposed' control group: children with a history of proven SARS-CoV-2 infection (RT-PCR, antigen test or serology positive) who were 0-18 at the time of SARS-CoV-2 infection.
Children (with help of their parents) collect their saliva with a saliva collection kit which they send to our research center.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Children with a history of MIS-C or Post-COVID Condition and children with a known SARS-CoV-2 infection without severe disease course.
Leiden University Medical Center
Leiden, South Holland, 2333ZA, Netherlands
Saliva
Emmeline P Buddingh, MD, PhD
Leiden University Medical Center
First Submitted
February 9, 2023
First Posted
February 10, 2023
Study Start
June 28, 2022
Actual (reported)Primary Completion
January 31, 2024
Estimated (date passed)Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 10, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: